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and Applied Neurobiology Review: Microglia in motor neuron disease
Motor Neuron Disease (MND) is a fatal neurodegenera-
tive condition, which is characterized by the selective
loss of the upper and lower motor neurons. At the sites
of motor neuron injury, accumulation of activated
microglia, the primary immune cells of the central ner-
vous system, is commonly observed in both human post
mortem studies and animal models of MND. Microglial
activation has been found to correlate with many clini-
cal features and importantly, the speed of disease pro-
gression in humans. Both anti-inflammatory and pro-
inflammatory microglial responses have been shown to
influence disease progression in humans and models of
MND. As such, microglia could both contribute to and
protect against inflammatory mechanisms of pathogen-
esis in MND. While murine models have characterized
the microglial response to MND, these studies have
painted a complex and often contradictory picture, indi-
cating a need for further characterization in humans.
This review examines the potential role microglia play
in MND in human and animal studies. Both the pro-in-
flammatory and anti-inflammatory responses will be
addressed, throughout the course of disease, followed
by the potential of microglia as a target in the develop-
ment of disease-modifying treatments for MND.
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Motor neuron disease
Motor Neuron Disease (MND) is a fatal neurodegenera-
tive condition characterized by the progressive degener-
ation of both upper motor neurons in the motor cortex,
and the lower motor neurons in the brain stem and
spinal cord [1]. MND has a number of subtypes, of
which Amyotrophic Lateral Sclerosis (ALS) is the most
common and affects around two in every 100 000 peo-
ple [2]. Throughout much of the literature, ALS and
MND are used synonymously; here MND will be used
to refer to all subclasses of the disease.
Typically, MND presents with progressive muscle
weakness in the extremities, muscular atrophy,
fasciculations, cramping, spasticity and fatigue [1].
Diagnosis of MND normally occurs around 55–
60 years of age. While survival time varies from just a
few months to decades [3], 80% of patients survive
only two to five years after diagnosis, with death usu-
ally resulting from paralysis and respiratory failure [1].
Currently there is no cure, and the only US Food and
Drink Administration-approved treatments, Riluzole
and Edaravone, have modest effects, extending survival
by mere months [1].
MND is pathogenically complicated, and the cause of
MND in most cases is unknown: 90–95% of cases are
sporadic (sMND), while the remaining 5–10% are
familial (fMND), generally with autosomal dominant
inheritance [4]. More than forty pathogenic mutations
have been associated with MND, including mutations
in SOD1 (Superoxide dismutase) [5], TARDBP which
encodes Transactive Response DNA-binding protein 43
kD (TDP-43) [6], FUS (RNA Binding Protein Fused in
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Sarcoma/Translocated in Sarcoma) [7,8], and the most
common, C9orf72 (chromosome 9 open reading frame 72)
[9]. Interestingly, a number of MND-associated genes
have a direct role in immunity, such as TBK1 [10],
OPTN [11], VCP [12] or pathways that are important
for immune function, such as the autophagy and lyso-
somal pathways (e.g. SQSTM1 [13], UBQLN2 [14]).
Neuropathology of MND
There are many pathological changes associated
with MND including depletion of giant pyramidal (Betz)
cells and atrophy of the precentral gyrus, thinning of
the spinal ventral roots, sclerosis and pallor in the
corticospinal tracts and loss of lower motor neurons
[15].
The hallmark microscopic pathology of MND is the
presence of protein aggregates in the remaining motor
neurons. In the majority of cases, these aggregates are
composed of ubiquitylated TDP-43 [6]. However, aggre-
gates may also include or be composed of other pro-
teins including FUS and SOD1 [16]. TDP-43-positive
inclusions are primarily seen in the motor structures of
the spinal cord, corticospinal tract and the motor cor-
tex [17]. These inclusions are also observed to a lesser
and more variable extent in extramotor regions includ-
ing the anterior frontal and temporal cortices [18].
MND is considered to be on a disease spectrum with
Frontotemporal Dementia which is characterized by
changes in personality and behaviour, loss of language
skills and cognitive decline [19]. Along this continuum
cases show pathology purely in motor regions, ranging
to FTD cases with purely nonmotor region pathology
[18]. This spectrum is reflected clinically with some
MND patients displaying purely motor symptoms, some
patients having both motor and cognitive or beha-
vioural decline and some FTD patients without motor
symptoms.
Glial involvement in MND
In models of MND, motor neurons show dysfunction in
many cellular processes including axonal transport and
microtubule function [20,21], RNA processing [22],
endoplasmic reticular stress response [23] and endoso-
mal trafficking [24]. However, MND is not a purely
neuron-autonomous disease; glial cells are highly
involved and also display inclusion pathology both in
human MND and in animal models [25,26]. Microglio-
sis and astrogliosis, the emergence of activated micro-
glia and astrocytes respectively, can be seen in human
post mortem tissue and animal models [27,28]. Further,
in a chimeric mutant SOD1G93A mouse model, mutant
SOD1 (mSOD1) expressing motor neurons showed
improved survival when surrounded by wild-type astro-
cytes and microglia, and in contrast, wild-type motor
neurons showed MND pathology when surrounded by
mSOD1 glia [29], indicating that the glial environment
influences neuronal pathology in MND. While infiltrat-
ing immune cells, such as mast cells, T cells, dendritic
cells and macrophages, are also a feature of MND
[27,30,31], the remainder of this review will focus on
the complex role microglia play in the progression of
MND.
Microglia – the primary immune cells of
the central nervous system
Microglia are the resident immune cells of monocytic
lineage and are the primary form of immune defence
within the central nervous system (CNS). These highly
active cells have several functions in development,
homeostasis and innate immunity [32].
Under homeostatic conditions, microglia have a ram-
ified morphology with small somata and short, fine pro-
cesses that constantly extend, retract and reform in
order to survey the local microenvironment [33].
Under pathological conditions, microglia have functions
in pathogen destruction, the resolution of inflammation
and the promotion of healing and cell growth. Micro-
glia react to signals from potential pathogens (Patho-
gen-Associated Molecular Patterns; PAMPs), and
signals expressed by damaged endogenous cells (Dam-
age-Associated Molecular Patterns; DAMPS), via the
activation of pattern recognition receptors [34]. In
response, microglial cytoplasmic processes swell and
shorten, becoming less ramified, and at the extreme
end of the spectrum, the cell can adopt a large, ‘amoe-
boid’ morphology (Figure 1). This activation is associ-
ated with alterations in the molecules that they
express. Once the activating stimulus has been
resolved, microglia may revert to their homeostatic
ramified state.
However, with ageing and chronic activation micro-
glia have been observed to adopt another phenotype,
often referred to as the dystrophic phenotype [35,36] .
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These cells show reduced surveillance and dendritic
branching [37], a redistribution of Iba1- particularly in
the processes [38] and reduced motility and migration
[39]. Furthermore, these cells show changes in gene
expression including expression of pro-inflammatory
cytokines in homeostatic conditions [40] and more sus-
tained responses to damage [39], as well as storage of
iron as ferrate [41]. As this phenotype is most com-
monly observed in the ageing brain, this dysfunctional
phenotype may represent microglial senescence.
Microglia present a multifaceted inflammatory
response. This includes the release of pro-inflammatory
cytokines and reactive oxygen and nitrogen species to
aid the destruction of pathogens and damaged cells.
Chemokines may be released to further activate and
recruit other glial and immune cells to the site of injury
[32]. Microglia also have functions relating to inflam-
mation mediation and resolution, debris clearance, tis-
sue healing and growth. This is achieved firstly, via the
release of anti-inflammatory cytokines and trophic fac-
tors, which promote healing, repair and tissue remod-
elling. Secondly, they may increase the number of
surface scavenger receptors to promote pathogen and
debris phagocytosis [42].
Historically, activated microglia have been classified
as pro-inflammatory (M1) or anti-inflammatory (M2).
However, this binary system has received criticism. It
has been suggested that activated microglia may fall on
a spectrum, with some cells being purely M1 through
to some cells which show a purely M2 phenotype
[43,44]. However, transcriptomic profiling of ex vivo
and in vivo microglia isolated from mouse models of
various neurodegenerative conditions, failed to find evi-
dence of an M1/M2 spectrum, with many microglia
exhibiting disease-specific profiles [45,46]. Furthermore,
single-cell-based analyses of microglia from both mouse
and human cortex have revealed several transcription-
ally distinct phenotypes which differ from the M1/M2
phenotypes [47,48]. This said, a lot of the literature
still follows this type of characterization and uses clas-
sic inflammatory markers to determine microglial func-
tion. As such, in this review, we will focus on
microglial functions and will use the terms pro-inflam-
matory and anti-inflammatory to broadly describe
microglial activation. However, these terms are used
with caution and the reader is respectfully advised to
bear in mind that this is done as a ‘shorthand’ to ease
discussion. We do not wish to imply that we endorse a
simple binary classification.
A brief summary of some of the main molecules
associated with microglia is given in Table 1. Microglial
phenotype is affected by a number of complex factors
including location within the CNS [49,50], microglial
age [51], activating stimuli and disease [47], as well as
well as differences between human and murine micro-
glia [51]. Furthermore, microglia may express mole-
cules with pro-inflammatory and anti-inflammatory
functions simultaneously. Therefore, it should be noted
that Table 1 is not a comprehensive list and is focused
more on findings related to neurodegenerative disease,
particularly MND.
Microglial activation is effective in the short-term
removal of damaged cells and pathogens and is neces-
sary for the protection of the CNS. However, where
Figure 1. Microglial morphology. In their resting state microglia
have a ramified morphology. Once activated, their cytoplasmic
processes swell such that the cell ultimately adopts a large
amoeboid morphology. Upon resolution of the activating stimulus,
microglia revert to their ramified state. With aging microglia can
adopt a dystrophic phenotype characterised by loss and beading
of the processes and fragmentation of the cytoplasm.
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Table 1. Summarization of microglial phenotypes, their activating stimuli and typical markers for their identification
Associated functions
Homeostatic state and pathogen
detection
Pathogen destruction- associated
with inflammation
Inflammation suppression and
phagocytosis
Tissue remodelling and
extracellular matrix
deposition
Upregulated cytokines TNF-a, IL-1b, IL-1a, IL-6, IL-12a,
IL-12b, IL-15, IL-18, IL-23, IL-
33, IFN-c
IL-4, IL-10, IL-13 ARG1*,
TGF-b, FIZZ1*
IL-10
Chemokines CCL1, CCL2 (MCP-1), CCL3, CCL4,
CCL5, CCL8, CCL12 (MCP-5),
CXCL2, CXCL4, CXCL9,
CXCL10, CXCL13
CXCL16, CCR2 (CD192), CXCL13
Enzymes HEXB+, NOX2 (CYBB), NOS2, iNOS,
CASP1 (ICE), COX2
MMP-12, ARG1*?, YM1*?
Receptors and
Transmembrane Proteins
TGFBR1+, P2RY12+, P2RY13+,
FCRLS*, TMEM119+, GPR34+,
SIGLEC-H+, CD11b (ITGAM),
Iba1(AIF1*), CXC3R1, CSF1R
MHC II receptors including HLA-
DR, IFNar1, IFNar2, CD45,
CD119 (IFNgr1), CD14, TLR-2,
CCR8,
CD163, CD204, IFNAR1,
IFNAR2, IL-10RA, CD68,
IFITM3, CD16 (FcyRIII),
CD32 (FcyRII), CD33,
CD64, TREM2*?
MHCII, CCR8
Growth factors IGF1 BDNF
Transcription and
signalling factors
SALL1+, PU.1, IRF1, STAT3
Other OLFML3+, GLUT5, ROS S100A8, S100A9, IRAK1 OPTN, DAP12 (TYROBP),
GRN,
References [47,142–145] [32,47,145–151] [47,145–147,151] [32,47,146,151–153]
Key: mouse specific*; Human expression uncertain*?; Result from In-vitro study; Microglial Marker/Signature Gene+
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the initial trigger is not resolved, a destructive cycle of
microglial activation and neuron death is initiated
(Figure 2). Briefly, this cycle can be triggered by
PAMPs causing microglial cytotoxicity leading to neu-
ronal death. Alternatively, if neuron death is triggered
by processes such as protein misfolding and aggrega-
tion, or excitotoxicity, DAMP release can cause cyto-
toxic microglial activation with increased
inflammation and neuronal death [52]. This process is
seen as a driver of progression in neurodegeneration
[52,53].
Microglial activation in human MND
Human studies have demonstrated the importance of
microglia in MND. Post mortem spinal cord from MND
patients has been found to contain raised levels of
Monocyte Chemoattractant Protein 1 (MCP-1; more
commonly known as C-C Motif Chemokine Ligand 2 or
CCL2), a key recruiter of microglia [31]. At sites of
neuronal loss, immunohistochemistry for key markers
of microglia/macrophages, Cluster of Differentiation
(CD) 68 and Ionized calcium binding adaptor molecule
1(Iba1), reveals microglia that have transitioned from
their ramified morphology to the ‘activated’ morphol-
ogy described above [31,54,55].
A population of microglia, which are immunopositive
for the haemopoetic transmembrane phosphoglycopro-
tein, CD34, have been observed in the ventral horn of
sMND spinal cord [56]. In control cases, immunoreac-
tivity for CD34 is restricted to the blood vessels and
capillaries. However, in MND cases, CD34+ cells were
found interspersed throughout the ventral horn form-
ing clusters around motor neurons. These cells showed
a rounded morphology, with a small subset staining
positively for the microglial/macrophage marker Iba1.
These cells were also Ki67+, indicating that these cells
may represent an alternative, proliferative microglial
phenotype.
The presence of activated microglia is associated with
a number of key pathological and clinical features of
MND. Increased microglial activation has been
observed in the key sites of neuronal degeneration, as
indicated by increased expression of CD68 and Iba1 in
post mortem motor cortex and spinal cord, compared to
control [54]. This has also been observed to a lesser
extent in nonmotor regions including the amygdala,
hippocampus and the middle frontal and superior tem-
poral gyri [54]. Furthermore, the presence of Iba1+
microglia correlated with the extent of neuronal loss in
the motor cortex, spinal cord and middle frontal gyrus,
while increased microglial activation in the middle
frontal cortex and superior temporal gyrus was associ-
ated with impaired executive function [54].
Additionally, increased microglial activation, as illus-
trated by CD68 and Iba1 immunostaining, in the corti-
cospinal tract has been significantly associated with
more rapid disease progression [55]. Familial cases
associated with C9orf72 mutations tend to show more
extensive microglial pathology within the corticospinal
tract [55]. Reactive microgliosis has also been described
in MND cases associated with other disease-causing
mutations such as TBK1 [57], SOD1 [58], FUS [59],
and ANG [60]. Furthermore, higher scores on a clinical
upper motor neuron assessment scale, based on the
Ashworth Spasticity Scale, are associated with
Figure 2. The cycle of microglial/ neuronal neurotoxicity. The
toxicity cycle can be started in two ways. First, an external
stimulus directly activates microglia, which produce cytotoxic
factors that cause neuronal damage. Secondly, neuronal damage
can be initiated by another pathological trigger, which results in
the release of DAMPs, which in turn activates microglia, resulting
in a toxic environment for other neurons (reactive microgliosis).
This results in a self-perpetuating cycle of microglial over-
activation and neuronal damage.
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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increased microglial pathology in the upper corti-
cospinal tract. [55]
While such autopsy studies represent end-stage dis-
ease, these findings are supported by in vivo Positron
Emission Tomography imaging, where neuroinflamma-
tion in MND was observed using the 18-kDA transloca-
tor protein (TSPO) PK11195 tracer ligand [61]. The
binding of this ligand is highly associated with acti-
vated microglia but has also been observed in other cell
types including astrocytes, and is associated with neu-
roinflammation. In comparison with neurologically
healthy individuals, MND patients showed increased
signal in both motor regions and extramotor regions. A
further PET study showed neuroinflammation in MND
to be associated with cortical thinning and a worse dis-
ease phenotype as indexed by the ALS Functional Rat-
ing Scale [62]. Caution is required in interpretation of
these results due to the lack of specificity of the
marker.
Studies of a microglial regulatory protein, Triggering
Receptor Expressed on Myeloid cells 2 (TREM2) have
also implicated microglia in MND. TREM2 is a mem-
brane-bound protein, which is expressed by multiple
myeloid cell populations including microglia, and pro-
motes myeloid activation and phagocytosis, and down-
regulates the transcription of pro-inflammatory
cytokines [63]. Soluble TREM2, a cleaved form of the
protein, was found to be upregulated in human MND
patient spinal cord and associated with improved
patient survival [64,65]. Furthermore, soluble TREM2
mRNA has been found to be highly expressed in cere-
brospinal fluid (CSF) in the early stages of MND and
diminished in later stage disease [65]. In the late stages
of disease, TREM2 expression correlated with survival
time in MND patients, perhaps reflecting a continued
neuroprotective response [65]. A rare TREM2 missense
variant (p.R47H) that dampens microglial neurotoxic-
ity has been identified as risk factor for neurodegenera-
tive conditions including Alzheimer’s disease (AD) [66]
and potentially MND, although results have varied
[64,67].
A recent study by Zhou et al. [68] has shown that
TREM2 has a key role in regulating disease-associated
microglial gene expression in both human AD and in
mouse models of AD using single nuclear RNA
sequencing, supporting the role of TREM2 in microglial
gene expression regulation. However, microglial gene
expression differed greatly in humans compared to
mouse models of AD, indicating a species-specific role
for TREM2 in microglial regulation. Furthermore, while
TREM2 is highly associated with microglial activation
and regulation, the expression of TREM2 by human
microglia has recently been questioned; TREM2
immunohistochemistry on human cortical tissue
showed that TREM2 was overwhelmingly expressed by
infiltrating monocytes, while little expression was
observed in native microglia [69]. Such species-speci-
ficity stresses the need for human as well as animal
research.
Cerebrospinal fluid from MND patients has shown
high levels of inflammatory cytokines including TNF-a,
IL-1b and IFN-c [70–72]. Furthermore, microarray
transcriptomic analysis of human spinal cord grey mat-
ter has shown an increase in inflammatory signalling
in MND, characterized by various interleukins and
cathepsins [73].
In summary, human pathology, imaging and genetic
studies have supported a role for microglia in MND.
The small amount of published research that attempts
to determine specifically which microglial functions are
relevant in human MND favours an inflammatory
process.
Microglial function in animal models of
MND
Attempts to determine the molecular behaviours of
microglia in MND with greater specificity have predom-
inantly utilized transgenic animal models. The first
made, and most widely utilized and characterized MND
model was generated in mice using the familial G93A
mutation in the SOD1 gene [74]. Further mSOD1 mod-
els have been developed using other patient variants
[75–77]. The mSOD1 models rely on high transgene
copy numbers, which produces a widespread overex-
pression of mutant protein, resulting in a reliable but
severe disease phenotype [78]. While each variant dif-
fers in terms of the age of disease onset, rate of disease
progression and symptom presentation, generally the
mSOD1 models show extensive MN loss, aggregates of
misfolded protein, progressive paralysis and shortened
life span [79].
Following this, models have been created which
contain transgenic mutations in TARDBP, FUS,
C9orf72, PFN1 and UBQLN2 (summarized by Lutz
[79]), as well as in other species including rats [80]
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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and zebrafish [81–83]. The MND models replicate
many of the key features of disease and have provided
a mechanism to study the progression of MND pathol-
ogy. However, these models often show more aggres-
sive disease progression compared to the human
disease, and as it is the case with all disease models,
no one model is able to replicate all disease features
[78].
Microglia in early phase disease in animal models.
Research to ascertain whether microglial changes are
involved in the initial stages of pathology in murine
models of MND have reported conflicting findings.
mSOD1G93A mice show evidence of peripheral nerve
and motor neuron dysfunction early, before the appear-
ance of CD68+ macrophages and microglia in the mus-
cle and spinal cord respectively [84]. In contrast,
decreased levels of Iba1+ microglia in mSOD1G93A mice
spinal cord, prior to symptom onset have also been
reported [85]. Furthermore, no change in microglial
number was observed in mSOD1G93A rat spinal cord
isolated at the equivalent presymptomatic stage [28].
However, a significant increase in the number of micro-
glia was observed immediately postsymptom onset
[28]. These mixed findings make it difficult to deter-
mine whether microglia are actively involved in the
initial motor neuron pathology, or whether neuroin-
flammation is secondary to motor neuron pathology.
Given the microglial functions associated with CD68
(phagocytosis) and Iba1 (motility), these data could
suggest that microglia may be recruited to the sites of
neuronal pathology before the appearance of symp-
toms, whereas the CD68+ microglia may reflect micro-
glia responding to the damage already present.
Additional phenotypic investigation of microglia in
MND is required to characterize their role in humans.
In the later disease stages, animal models have tended
to focus on the trophic and anti-inflammatory, versus
neurotoxic or pro-inflammatory effects of microglia.
These roles will now be considered in turn.
Anti-inflammatory and trophic microglia in animal
models of MND
In the early stages of most diseases, microglia are acti-
vated by signals from damaged or stressed neurons,
and potential pathogens [86]. In MND, these signals
are likely to include various chemokines and DAMPS
released by motor neurons, and the uptake of misfolded
protein aggregates by microglia [87,88]. Transcrip-
tomic analysis of microglia isolated from 11-week-old
mSOD1G93A mice has shown high levels of Ym1, an
anti-inflammatory macrophage marker, as well as
Brain-derived Neurotrophic Factor (BDNF), a neu-
rotrophin which promotes neuronal survival [44].
Interestingly, these microglia were also found to
express increased mRNA transcripts for CD163, a hap-
toglobin-haemoglobin scavenger receptor predomi-
nantly expressed by perivascular macrophages and by
microglia, following breakdown of the blood-brain bar-
rier [89], indicating this process could occur early in
disease. Coculture of these microglia with wild-type
motor neurons promotes neuronal survival, but only in
the presence of astrocytes, potentially indicating a neu-
roprotective microglial response and a possible interde-
pendence with astrocytes – however further evidence is
needed to validate the microglial/astrocytic interaction.
A further study of microglia from presymptomatic
mSOD1G93A mice has demonstrated a 16-fold increase
in IL-10 production, a cytokine responsible for inflam-
matory cytokine downregulation [90]. Conversely, tar-
geting IL-10 overexpression in the spine resulted in
delayed symptom onset and extended survival, while
blocking IL-10 receptors using the mIL-10R1 antibody
results in rapid precipitation of symptoms. Increased IL-
10 expression is associated with reduced TLR-2 activ-
ity, which promotes microglial inflammatory cytokine
production [91].
Together, these results indicate that microglia, in the
presymptomatic stages of MND may counteract or pre-
vent the inflammatory response associated with later
disease stages potentially delaying symptom onset.
Pro-inflammatory microglia in animal models of
MND
Transcriptional analysis of 11-week-old mSOD1G93A
mouse spinal cord homogenates has demonstrated a
significant upregulation of inflammatory genes includ-
ing cathepsin D and TNF-a [92]. This was thought to
represent an inflammatory response in the presymp-
tomatic stage. However, symptom onset has been
observed at as early as 8.5 weeks of age in this model
[85], implying that the inflammatory microglial pheno-
type observed actually occurs in the early,
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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postsymptom-onset stage of disease. Furthermore, these
results contradict other findings of increased anti-in-
flammatory cytokine expression at the same age in the
same mSOD1G93A model [44].
The latter study went on to examine late-stage
mSOD1G93A mice and found a shift towards diminished
anti-inflammatory markers and high levels of nitric
oxide, a toxic immune mediator. Coculture of these
late-stage microglia with wild-type motor neurons
induced neuronal death [44], likely by increasing
motor neuron sensitivity to glutamate, potentially
resulting in excitotoxicity [93], a known feature of
motor neuron pathobiology in MND. These microglia
also appear to inhibit the protective uptake of gluta-
mate by astrocytes in culture [93].
Microglia expressing mSOD1 appear to be more neu-
rotoxic than wild-type microglia. Upon stimulation with
the neurotoxicity-inducing PAMP, Lipopolysaccharide
(LPS), microglia overexpressing mSOD1G93A released
more NO and superoxidase, than both microglia over-
expressing wild-type SOD1, and wild-type microglia
[94,95]. These mSOD1 microglia induced more neu-
ronal death in coculture with motor neurons than their
wild-type counterparts.
Interestingly, Weydt and colleagues [96] performed
a similar experiment, but compared primary microglia
from 3-day-old mice and 60-day-old mice (early
symptomatic). Upon stimulation with LPS, only the
adult mSOD1G93A microglia showed a significant dif-
ference from the wild-type control, with increased
TNF-a production and decreased IL-6 expression. This
suggests that adult and not perinatal mSOD1-express-
ing microglia are more neurotoxic than wild-type
microglia.
This heightened response by aged mSOD1 microglia
may reflect microglial priming, where microglia display
an exaggerated response to stimuli after prior activa-
tion, such as exposure to mSOD1 [97]. Microglial prim-
ing is a feature of ageing and other neurodegenerative
conditions such as Alzheimer’s disease [98]: these
microglia are less responsive to anti-inflammatory
agents, promoting chronic inflammation [98].
Furthermore, transplantation of wild-type microglia
into mSOD1G93A mice, via bone marrow transplant,
results in reduced MN loss and extended survival [95],
indicating that in mSOD1 mice, treatment with wild-
type microglia is sufficient to benefit motor neurons
and consequentially mouse survival.
Further evidence of microglial toxicity in MND mur-
ine models comes from experiments with CX3CR1 gene
manipulations. CX3CR1 encodes the receptor for the
chemokine fractalkine. Together, this ligand and recep-
tor mediate neuron-microglial interactions and protect
neurons by preventing pro-inflammatory microglial
activation [99]. The V249I variant of CX3CR1 is asso-
ciated with faster progression and shorter survival in
human sMND [100]. Transgenic mSOD1G93A bred with
CX3CR1-/- mice produced a worsened MND phenotype
with enhanced inflammatory microglial activation and
decreased neuronal density compared to mSOD1/
CX3CR1+/-, mSOD1 mice and wild-type mice [101].
Interaction of microglia and MND-associated
proteins
A number of the proteins associated with misfolding in
MND appear to influence microglia. Phagocytosis of
extracellular mSOD1 has been shown to cause pro-in-
flammatory activation of microglia [102]. On incuba-
tion with mSOD1 aggregates, primary mouse microglia
adopted the amoeboid morphology. Real-time quantita-
tive PCR (RT-qPCR) revealed increased expression of
the inflammatory factors TNF-a, IL-1b, NADPH oxidase
2 (NOX2) and superoxidase, and a concomitant
decreased expression of the repair factor IGF-1. When
cocultured with primary mSOD1G93A mouse motor
neurons, these primed microglia proved to be neurotox-
ic, compared to un-primed mSOD1G93A microglia. How-
ever, incubation of mSOD1 aggregates with motor
neurons alone had no significant effect on motor neu-
ron survival, indicating that extracellular mSOD1 is
not directly toxic to motor neurons alone, and activa-
tion of microglia to a pro-inflammatory phenotype is
required for neurodegeneration. Motor neuron death
could be attenuated, by using antibodies to block TLR-
2 and 4, and CD14, indicating a potential TLR-CD14-
mediated pathway by which mSOD1 is able to induce
the neurotoxic microglial phenotype.
Similarly, mutant TDP-43 (mTDP-43) has been
shown to induce an exaggerated pro-inflammatory
microglial phenotype characterized by TNF-a, IL-1b
and NOX2 in primary mouse microglia, compared with
wild-type treated with TDP-43 or nontreatment [103].
Furthermore, the expression of mTDP-43 by microglia
produces a more pro-inflammatory response to LPS
stimulation compared to wild-type microglia in vitro
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[104]. mTDP-43 appears to activate microglia through
the nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-jB) pathway [103]. The NF-jB path-
way is a master regulator of inflammation, and is
highly upregulated in MND patient spinal cord, and
mSOD1 mice [104,105]. When activated, the NF-jB
complex relocates to the nucleus, inducing further pro-
inflammatory cytokine and chemokine expression
[106]. The NF-jB pathway can be induced directly via
pathologically truncated wild-type TDP-43 and even
more potently by mTDP-43 in primary mouse microglia
[103]. This results in the production of pro-inflamma-
tory cytokines [103,105]. Additionally, NF-jB-activated
mSOD1 microglia have been shown to attack healthy
synapses in vitro, causing axonal damage, a feature not
observed in wild-type microglia [105].
Thus, the accumulation of pathological, misfolded
SOD1 and TDP-43 may contribute to a switch in
microglial phenotype from an initially anti-inflamma-
tory response to a pro-inflammatory phenotype.
Interestingly, recent research has indicated that dys-
functional microglia may contribute to the pathological
translocation of TDP-43 from the nucleus to the cyto-
plasm. Using a transgenic zebrafish model, which coex-
presses green fluorescent protein-tagged TDP-43 and
microglia which express mCherry, Svahn et al. [107]
visualized the nucleocytoplasmic transmission of TDP-
43 and microglial dynamics in vivo. After initiating
neuronal death by ultraviolet light, microglia rapidly
approached and phagocytosed damaged neuronal
somata as well as TDP-43 granules in the nucleus.
Microglia were then depleted using a morpholino tar-
geted at the macrophage transcription factor, PU.1.
Ultraviolet light treatment in the absence of functional
microglia resulted in the translocation of TDP-43 from
the nucleus to the cytoplasm, a key feature of MND
pathobiology. This quite artificial model of neuronal
death indicates that dysfunctional microglial phagocy-
tosis may contribute to the typical pathological translo-
cation of TDP-43.
Finally, as noted above, hexanucleotide expansions
in C9orf72, the most common genetic cause of MND,
are associated with reduced expression of the C9orf72
protein. RNA sequencing and mass spectrometry have
led to the suggestion that microglia have the highest
C9orf72 levels of any cell type in mice [108,109]. In
contrast, another study suggested that there are lower
C9orf72 levels in microglia than neurons. This study
used a mouse strain which carried a LacZ reporter in
the C9orf72 orthologue, which was detected by b
galactosidase staining. However, as b galactosidase is
also a senescence marker, this result could reflect high
neuronal senescence rather than low microglial
C9orf72. Surprisingly, mouse models in which the
C9orf72 orthologue has been knocked down, generally
do not display motor neuron pathology as expected.
Instead, they have autoimmune-like conditions with
microglial and macrophage dysfunction [110,111]
together with increased inflammatory cytokines in
serum [111] and spinal cord [110]. Furthermore,
C9orf72 knockdown microglia and macrophages
appear to display lysosomal dysfunction, which may
result in a reduced ability of microglia to clear cellular
debris. Transcriptomic characterization of these micro-
glia revealed a predominantly inflammatory phenotype,
with increased expression of TNFa and IL-1b, in knock-
down mice compared to controls [110]. Together, these
results imply that the reduced levels of C9orf72 would
be associated with an inflammatory microglial response
and lysosomal dysfunction in macrophages, features
commonly observed in MND models [112].
The presence of discrete microglial phenotypes
Older research (predominantly in transgenic mouse
models with MND-causing SOD1 mutations) has raised
the possibility of two phases of microglial activation: an
earlier phase prior to symptom onset in which micro-
glia express more genes historically associated with
anti-inflammatory processes, followed by a later phase
associated more so with expression of pro-inflammatory
factors with the disease progression [44,113–116].
However, transcriptional studies using the same
model have had conflicting results, with microglia
expressing molecules classically associated with both
anti- and pro-inflammatory functions throughout dis-
ease. Flow cytometry and RNA sequencing of microglia
from mSOD1G93A mouse spinal cord over different dis-
ease time points have revealed simultaneous upregula-
tion of pro-inflammatory genes such as TNF-a, IL-1b,
and receptors for IFNs, and NOX2 , as well anti-inflam-
matory genes such as Insulin Growth Factor-1, Progran-
ulin and DAP12 / TYROBP [45]. These microglia
significantly differed in phenotype to those WT micro-
glia stimulated with LPS, indicating a disease-specific
profile.
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Table 2. Summary of transcriptomic studies of microglia in mSOD1G93A models
Type of model
(treatments
conditions)
Method of microglial
isolation Location
Stage of disease
Method References
Presymptomatic
stage
Symptom Onset –
Early stage Late/end stage
mSOD1G93A
mouse spinal
cord
homogenate
Not Applicable lumbar spinal
cord [L1-L5]
No change ↑Caspase-1, ↑TNF-a,
↑JAK3, ↑CD68,
↑Retinoid X
receptor a,
↑Homeobox
proteins,↑GABAA-
R
↑↑Vimentin, ↑↑CD147, ↑Caspase-1,
↑↑Bcl-xL ↑↑Cathepsin-D, ↑↑TNF-
a, ↑↑JAK3, ↑↑CD68, ↑GABAA-R
cDNA microarray,
macroarray and RT-
qPCR
[92]
mSOD1G93A
mouse
microglia
Flow Cytometry
(CD11b and CD16/
CD32)
Lumbar Spinal
Cord
Not measured ↑NOX2 ↑↑NOX2, ↓BDNF, ↓Ym1, ↓↓CD163 RT-qPCR [44]
mSOD1G93A
mouse
microglia
Sequential Percoll
gradient
centrifugation and
magnetic bead
isolation. Antibodies
conjugated to CD11b
Total spinal cord ↑MMP-12,
↑IGF,
↑Optineurin,
↑NOX2
↑↑IGF, ↑↑Optineurin,
↑↑NOX2, ↑TNF-a,
↑IL-1B, ↑TREM2,
↑Progranulin, ↑↑
MMP-12
↑↑↑IGF, ↑↑↑Optineurin, ↑↑↑NOX2,
↑↑MMP-12, ↑↑Progranulin,
↑↑TNF-a, ↑↑IL-1B, ↑IL-a
↑TREM2, ↑DAP12,↑IL-10,
↑ApoE, ↑Tau, ↑Osteopontin
Microarray and
RNAseq [over 1000
genes were
differentially
expressed therefore
only given a sample)
[45]
mSOD1G93A Rat
microglia
Magnetic Bead Column
Purification
Antibodies
Conjugated to
CD11b/c
Cortex No change RT-qPCR [28]
Brain Stem No change ↑Osteopontin,
↑Galectin
↓TNF-a, ↓IL-6, ↑↑Osteopontin, ↓IL-
10, ↑VEGF, ↑↑Galectin
Spinal cord:
Cervical [C1-
C7]
↑MCP-1 ↓TNF-a, ↑MCP-
1,↑Osteopontin,
↑VEGF,↑Galectin-3
↓IL-6, ↓↓TNF-a, ↑MCP-
1,↑↑Osteopontin, ↓Arg1,
↑↑VEGF,↑↑Galectin
Spinal Cord:
Thoracic [T2-
10]
No change ↓TNF-
a,↑Osteopontin,
↑Galectin, ↑VEGF
↓IL-6,↓↓TNF-a,↑↑Osteopontin,
↓↓↓Arg1,↑↑Galectin, ↑↑VEGF
Spinal Cord:
Lumbar [L1-
L5]
No change ↓TNF-
a,↑Osteopontin,
↓IL-10,
↑VEGF,↑Galectin
↓↓TNF-a, ↓IL-6,
↑↑Osteopontin,↓↓Arg1, ↓↓IL-10,
↓BDNF, ↑↑VEGF, ↑↑Galectin
mSOD1G93A
mouse
microglia
cultures (LPS
Treated
Adult
microglia)
Not Given - States
microglia were
isolated, purity
checked using
CD11b
immunostaining
Whole brain
(Foetal
Microglia)
No change
↑TNF-a,↓IL-6 Not measured Enzyme-Linked
Immunosorbent
Assay (ELISA)
[96]
Key: Inflammatory, Anti-inflammatory, and Other. Note: Arrows represent change in expression since last measured point and do not reflect the magni-
tude of change. All changes compared to control littermates apart from Nikodemova et al.28, which compared to wild-type mice.
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In comparison, RT-qPCR characterization of micro-
glia from mSOD1G93A rat spinal cord did not find
microglial activation in the presymptomatic stages of
disease [28]. However, at disease onset and late-stage
disease, mSOD1 microglia showed a simultaneous
upregulation of galectin and osteopontin, factors involved
in macrophage activation and chemotaxis, which have
been observed as being both neurotoxic and trophic,
and Vascular Endothelial Growth Factor (VEGF) a pro-
survival factor. This was accompanied by the concomi-
tant downregulation of the classic pro-inflammatory
marker TNF-a, and anti-inflammatory/ trophic markers
BDNF, IL-6 and arginase-1.
The same study showed microglial function to vary
according to location [28]: microglia from the cortex,
brain stem and the cervical, thoracic and lumbar spinal
cord regions were compared. The above differences
were only seen in the spinal cord, but not in cortical
regions. However, the cortical region where microglia
were sampled was not described. It is thus possible that
either unaffected cortices (such as occipital cortex)
rather than the motor cortex were sampled, or total
brain which may ‘dilute’ subtle changes. These differ-
ences in microglial transcriptome indicate that micro-
glial function may vary with both anatomical region
and disease stage. This and other studies [49,50] estab-
lish that the inflammatory environment, and the
inflammatory response to disease differs between
regions. It is thus important that the anatomical loca-
tion is clearly defined when performing such studies in
MND. It is also useful to consider more than one CNS
region in such research.
The most relevant mSOD1 murine studies of micro-
glial transcriptome have been summarized in Table 2,
highlighting the discrepancies in results. It is of interest
to note, even studies comparing the same regions of
spinal cord in mSOD1 mice at the same stage of disease
have shown differing results.
The inconsistency in these results likely reflects a
number of differences in the methodology, including
varying methods of gene quantification and the sample
isolation protocol e.g. isolated microglia versus tissue
homogenate versus cultured microglia. Microglial phe-
notype is highly dependent on their environment,
therefore removing these cells from their in vivo envi-
ronment will alter their transcriptional profile. Further-
more, microglia cell lines and cultures have been found
to be both functionally and transcriptionally different
to ex vivo microglia [117,118] .
Variability in the genetic background could also
cause variation in the results. In the mSOD1G93A
mouse model, four copies of the transgene, which
results in mSOD1 expression equivalent to those
expression levels seen in human MND, is insufficient
to produce symptoms in mice [74]. However, increas-
ing the transgene copy number not only results in
earlier symptom onset but also produces a more rapid
disease progression [74,119]. The genetic background
of the mice used for breeding has also been found to
alter the life span and rate of disease progression,
despite containing the same mutation and expressing
the same quantity of mutated protein [120–122]. This
potentially reflects the variability observed in humans,
with patients carrying G93C SOD1 mutations varying
in survival time from approximately 5 to 20 years
[123]. Moreover, the sex of the mice appears to affect
the rate of disease progression with various reports
indicating increased survival time and delayed symp-
tom onset in female mice compared to males
[121,124,125], as well as sex differences in response
to treatment [125–127].
Microglia as a therapeutic target
With their clear involvement in MND, microglia have
been a target in the development of therapeutic
options; the predominant aim being to reduce inflam-
mation34. The administration of anti-inflammatory
drugs has had mixed results in murine models and has
not translated well to humans. Minocycline, a tetracy-
cline antibiotic with broad spectrum anti-inflammatory
activity, has been found to cross the blood-brain bar-
rier, and reduce activity of inflammatory and pro-apop-
totic enzymes [128]. In early trials, administration of
minocycline was found to delay symptom onset and
improve survival in mSOD1G93A and mSOD1G37R mice,
if administered before symptom onset [129–131]. How-
ever, administration after disease onset accelerates
disease progression and increases microgliosis
[132,133], supporting a beneficial role for microglia in
the earliest stage of the disease. In human trials,
minocycline was found to increase the rate of decline,
significantly reducing lifespan [134]. Similarly, trials of
ceftriaxone (antibiotic), celecoxib (anti-inflammatory),
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and thalidomide (immunomodulatory drug) showed
promise in mSOD1 mice, but were ineffective in
humans [135,136]. Criticisms about the original ani-
mal trials have been raised including whether adequate
sample powering was employed, unaccounted con-
founding variables and the efficacy of administering a
drug before disease onset[137].
Another drug Clemastine, which reduces inflamma-
tion while increasing the expression of the anti-inflam-
matory cytokine arginase-1, has also failed to improve
disease in mSOD1G93A mice, unless administered within
the presymptomatic phase [138,139].
While attempts to dampen neuroinflammation have
given mixed results, targeting specific inflammatory
pathways has shown greater success. Inhibition of the
previously described NF-jB pathway in vitro in
mSOD1G93A microglia rescued motor neuron axon
length and survival time to levels seen with wild-type
microglia [105]. This was accompanied by reduced
expression of TNF-a and nitric oxide in mSOD1G93A
microglia, to levels observed in wild-type microglia
[105]. Transgenic NF-jB inhibition in mSOD1G93A
mice resulted in a 47% increase in life expectancy com-
pared to nontreated mSOD1G93A mice [105], emphasiz-
ing the effectiveness of targeting this pathway. Similar
manipulations have not yet been tried in humans.
Furthermore, there has been some success utilizing
treatments which aim to mimic the supportive micro-
glial functions in mSOD1 mouse models. The adminis-
tration of the trophic factors, VEGF and IGF-1, at
disease onset using viral vectors, has improved the
motor symptoms and extended survival time
[140,141].
Microglia show potential as a therapeutic target in
MND treatment. However, it is unsurprising that to
date, attempts in humans have been unsuccessful given
the conflicting findings observed in animal models of
MND, and our limited understanding of which micro-
glial functions are relevant to human MND.
Future directions
Research using animal models has shown that micro-
glia contribute to MND pathology with both toxic and
trophic functions. However, attempts to subclassify
microglial functions, based on the compounds
expressed by these cells, have been inconsistent. There-
fore, more work is required using human post mortem
CNS tissue to characterize the microglial phenotype
over the course of the disease.
Despite the inherent challenges that come with
using post mortem tissue, it has many benefits over
mSOD1 mouse models of MND. These models signifi-
cantly differ from human sporadic MND pathology.
Transgenic mSOD1 models greatly overexpress mSOD1
resulting in a severe phenotype that progresses much
faster than human MND [79] and could mask more
subtle pathological changes. Furthermore, mutations
in SOD1 are observed in only ~2.5% of all MND cases
[4], and represent a very specific form of MND.
Indeed, SOD1 fMND cases do not develop the hall-
mark ubiquitylated TDP-43+ inclusions seen in spo-
radic human MND and most forms of fMND,
including C9orf72, Angiogenin, Ataxin 2, and TANK
Binding Kinase 1 cases. Consequentially, mSOD1 mod-
els may not be representative of the majority of
human MND. Models have been developed using other
familial mutations, such as C9orf72, PFN1 and
TARDBP [79]. Some of these models do show charac-
teristic TDP-43 pathology. However, they also rely on
high transgene copy numbers to produce a phenotype,
and in some models (namely models utilizing muta-
tions in C9orf72) the disease phenotype can be unpre-
dictable, with a rapid disease progression and a
survival time of less than 6 months [79].
Furthermore, transcriptional single-cell sorting of
immune cells from the human cortex has demonstrated
several uncharacterized microglial phenotypes, with
some of them unique to humans [47]. This further sup-
ports the importance of transcriptional profiling in
humans as opposed to experimental models. Characteri-
zation of microglia isolated from different regions of
human brain and spinal cord using multiplexed single-
cell mass spectrometry has confirmed the presence of
distinct microglial populations in different locations
[48], in a similar manner to observations made in
mSOD1 murine models [28]. Therefore, it is important
to examine microglial transcripts separately across
regions of the brain and spinal cord, to better charac-
terize the different populations of microglia. It may also
be essential to characterize microglia in seemingly
unaffected areas, such as occipital cortex to determine
if there are microglial functions, which make these
regions less susceptible to MND pathology.
In summary, microglial activation is a clear feature
of MND; both in humans and mouse models, and thus
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modulation of the microglial phenotype in MND could
help to promote neuronal survival. However, we need
first to determine and identify which microglial func-
tions are important to human disease with TDP-43
proteinopathy.
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